{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Salmanton-Garcia J"],"funding":["European Hematology Association"],"pagination":["358-374"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11803548"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["100(3)"],"pubmed_abstract":["Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or"],"journal":["American journal of hematology"],"pubmed_title":["Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report."],"pmcid":["PMC11803548"],"funding_grant_id":["CRTH74"],"pubmed_authors":["Martin-Perez S","Papa MV","Marchesi F","Espigado I","Stojanoski Z","Delia M","Zak P","Magyari F","Sgherza N","Limongelli A","Fianchi L","Grafe SK","Weinbergerova B","Wojtyniak E","Batinic J","Stoma I","Aujayeb A","Pagano L","Falces-Romero I","Farina F","Mitrovic M","Pantic N","Leotta D","Visek B","Lahmer T","Colovic N","Drozd-Sokolowska J","Nappi D","Lopez-Garcia A","Criscuolo M","Cornely OA","Varricchio G","Schonlein M","Drgona L","Buquicchio C","Miranda-Castillo C","Labrador J","Erben N","Musto P","Navratil M","Bavastro M","Heras-Fernando I","Brunetti SC","Vinh DC","Petzer V","Cerchione C","Del Principe MI","Fracchiolla NS","Anastasopoulou AN","van den Ven L","Eisa N","Glenthoj A","Piukovics K","Tlusty J","Gavriilaki E","Salmanton-Garcia J","Davila-Valls J","Cuccaro A","Callejas-Charavia M","Aiello TF","Plantefeve G","Cordoba R","Dabrowska-Iwanicka A","Romano A","Almasari A","Mackenzie E","Samarkos M","Antic D","Sciume M","Merelli M","Idrizovic L","Cattaneo C","Garcia-Vidal C","Prezioso L","Arellano E","Pinczes LI","Prin R","Mayer J","Cvetanoski M","Biernat MM","Otasevic V","Cernan M","Marchetti M","Wolf D","Bilgin YM","Erdem S","van Praet J","Gora J","Busca A","Garcia-Ramirez P","Adzic-Vukicevic T","Vena A","Bakker M","Hersby DS","Khostelidi S","Magliano G","Coppola N","Khedr RA","Magdziak A","Dargenio M"],"additional_accession":[]},"is_claimable":false,"name":"Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.","description":"Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-03T02:48:12.666Z","creation":"2025-04-03T23:57:35.909Z"},"accession":"S-EPMC11803548","cross_references":{"pubmed":["39715069"],"doi":["10.1002/ajh.27565"]}}